EARNINGS: hVIVO CFO to retire; Personal Group sales and profit climb
15th Sep 2026 15:54
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
| Price | 7.00p on 28-09-2026 at 06:30:00 |
|---|---|
| Change | 0.00p 0% |
| Buy | 12.00p |
| Sell | 2.00p |
| Last Trade: | Buy 510.00 at 6.55p |
| Day's Volume: | 0 |
| Last Close: | 6.55p |
| Open: | 0.00p |
| ISIN: | GB00B9275X97 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 4.35p - 10.00p |
| Market Capitalisation: | £45.09m |
| VWAP: | 0.00p |
| Shares in Issue: | 688.40m |
Sector: Health Care and Related Services
Listed In: FTSE AIM 100, FTSE AIM All-Share,
hVIVO (HVO) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 510 | 6.55p | Ordinary |
16:40:37 - 25-Sep-26 |
| Buy* | 1,173 | 6.55p | Suspected BUY Trade |
16:36:05 - 25-Sep-26 |
| Sell* | 30,309 | 6.362p | Ordinary |
16:28:33 - 25-Sep-26 |
| Sell* | 55,939 | 6.425p | Ordinary |
16:20:32 - 25-Sep-26 |
| Sell* | 107,569 | 6.50p | Ordinary |
16:11:42 - 25-Sep-26 |
| Sell* | 17,500 | 6.35p | Ordinary |
16:07:32 - 25-Sep-26 |
| Buy* | 5 | 6.70p | Ordinary |
16:03:30 - 25-Sep-26 |
| Sell* | 1,887 | 6.35p | Ordinary |
16:02:30 - 25-Sep-26 |
| Sell* | 10,700 | 6.40p | Ordinary |
15:52:05 - 25-Sep-26 |
| Sell* | 11,812 | 6.40p | Ordinary |
15:50:39 - 25-Sep-26 |
hVIVO (HVO) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 22nd Sep 2026 7:00 am | RNS | Board Changes |
| 15th Sep 2026 7:01 am | RNS | Interim Results |
| 15th Sep 2026 7:00 am | RNS | Chief Financial Officer Succession |
| 8th Sep 2026 3:51 pm | RNS | Holding(s) in Company |
| 4th Sep 2026 7:00 am | RNS | Notice of Results |
| 27th Aug 2026 7:00 am | RNS | hVIVO acquires CRS Berlin |
| 23rd Jul 2026 7:00 am | RNS | H1 2026 Trading Update |
| 13th Jul 2026 7:00 am | RNS | Change of Auditor |
| 9th Jun 2026 7:00 am | RNS | Holding(s) in Company |
| 1st Jun 2026 12:00 pm | RNS-R | Consultancy contract with Decoy Therapeutics |